Table 3 Sample characteristics, PLHIV

Trenkwalder 1992 [46]

WR I-II (N = 17); WR III-V (N = 19); WR VI (N = 14)

NR

NR

NR

Arendt 1994 [47]

CDC II (N = 12); CDC III (N = 12); CDC IV C1 (N = 5); CDC IV C2 (N = 5); CDC IV D (N = 2); CDC IV B (N = 10)

NR

NR

NR

Beckley 1998 [50]

ASX (N = 2); CDC Stage A (N = 2); CDC Stage B (N = 2); CDC Stage C (N = 3)

Range 65–701; 5 participants had AIDS-defining CD4 counts (<200)

NR

Most were on zidovudine maintenance therapy

Bauer 2005 [7]

NR

NRx: 351 (282); NNRTI: 457 (375); PI: 320 (200)

HIV burden × 1000 copies/ml: NRx: 93.8 (163); NNRTI: 35.5 (102); PI: 20.1 (48.2)

NRx: N = 28; NNRTI: N = 25; PI: N = 37

Simmonds 2005 [49]

Based on CD4 count

ASX (CD4 > 200) (N = 52); AIDS (CD4 < 200) (N = 48)

Range 189.83 (183.27) - 386.36 (302.39)

Virions:

ASX 33545.25; AIDS 193401.00

NR

Dellepiane 2005 [48]

CDC classificationASX (N = 15); AIDS (group IV) (N = 15)

NR

NR

NR

Scott 2007 [35]

NR

408 (293)

log copies/ml

2.18 (0.94)

All were on a NRTI-based regimen, with 82% receiving a PI as a third agent

Richert 2011 [8]

CDC category C: 23%

^a520 (348, 709)

<500 copies/ml: 83%

89%

Bauer 2011 [22]

NR

BMI <21: 280 (52); BMI 21–29: 422 (40); BMI > 29: 361 (64)

Log10 viral load

BMI <21: 3.06 (0.34); BMI 21–29: 2.19 (0.26); BMI > 29: 2.08 (0.39)

% no ART/NNRTI-based ART/ PI-based ART: BMI <21: 38.2/26.5/35.3; BMI 21–29: 31.7/26.7/

41.7; BMI > 29: 37.0/18.5/44.4

Sullivan 2011 [21]

NR

M 537.4 (258.97); F 583.4 (103.55)

M 13597.6 (4654.88); F 4609.7 (3226.36)

HAART: N = 25; Non-HAART: N = 6; NRx: N = 9

Erlandson 2012a [10]

NR

^a551 (361, 768)

Detectable (≥48 copies/mL): 5%

NR

Erlandson 2012b [18]

NR

594 (16)

95% had plasma HIV-1 RNA < limits of detection

Any didanosine: Non-fallers: 57 (23); Single fallers: 10 (23); Recurrent fallers: 24 (36) Any stavudine: Non-fallers: 93 (37); Single fallers: 22 (51); Recurrent fallers: 33 (50) Efavirenz: Non-fallers: 86 (34); Single fallers: 10 (23); Recurrent fallers: 22 (33)

Cohen 2012 [45]

NR

556.4 (284)

Log ₁₀ HIV RNA:

^a3.50 (2.68, 4.42)

HAART: 76.9%

Beans 2013 [43]

NR

^a445 (265, 531)

Non-detectable (<400 copies/ml): 91%

Majority were receiving cART

Mbada 2013 [44]

All: Clinical stage I of HIV/AIDS (ASX HIV infection, with PGL)

NR

NR

100% HAART

Richert 2014 [9]

CDC stage C 24%

^a506 (340, 715)

HIV RNA level < 500 copies/ml: 84%

89% on ART

Erlandson 2014 [12]

NR

594 (303)

HIV-1 RNA < limits of detection: 95%

All participants taking effective cART